Premium
P1‐058: Nilvad: An Investigator Driven Phase III Multi Centre European Clinical Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease
Author(s) -
Lawlor Brian,
O'Dwyer Sarah,
Cregg Fiona,
Meulenbroek Olga,
Wallin Anders,
Coen Robert,
Anne Kenny Rose,
Olde Rikkert Marcel G.M.,
Kennelly Sean,
Borjesson-Hanson Anne,
Crawford Fiona,
Mullan Michael,
Pasquier Florence,
Molloy William,
Tsolaki Magda,
Howard Robert J.,
Lucca Ugo,
Riepe Mattias,
Kalman Janos
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.805
Subject(s) - medicine , dementia , clinical trial , placebo , disease , pathology , alternative medicine
trations of lithium were maintained at a range of 0.4-0.8mmol/L. We assessed verbal memory using delayed recall in Hopkins Verbal Learning Test-Revised (HVLT-R) at the start and end of treatment. Repeated-measures ANOVAwas used to compare delayed recall zscores over time, with cumulative lithium dose as a covariate. We also assessed stroke severity (National Institutes of Health Stroke Scale (NIHSS)) and cognition (Montreal Cognitive Assessment (MoCA), Standardized Mini-Mental State Evaluation (sMMSE)) at baseline and termination. Results: To date, 11 patients (45% male, mean (SD) age 1⁄4 70.3 (12.1), sMMSE 1⁄4 26.8 (3.4), MoCA 1⁄4 20.9 (5.0), HVLT-R delayed recall z-score 1⁄4 -1.3 (1.0)) have been recruited, on average, 87 (668) days after mild stroke (NIHSS score 2). Cumulative lithium dose received ranged from 0 (screen drop) to 26850 mg. Lithium was discontinued in 3 patients due to tolerability issues but there were no serious adverse events. Cumulative lithium dose was significantly associated with improvement in delayed recall over time (F1⁄45.41, p1⁄40.045). There was no change in the other measures. Conclusions:These initial results suggest that lithium treatment is tolerated by many post-stroke patients, and may be associated with improved verbal memory after stroke, with a preliminary signal suggesting a dose response relationship. These findings are consistent with lithium’s suggested neuroprotective and neurotrophic effects.